About Us

Established in 2014, Angsana Molecular & Diagnostics is a multinational company headquartered in Singapore, with offices in Hong Kong and Malaysia.


We specialise in developing premium genomic assays in four areas that have the largest impact on the Asian population. We not only provide clinicians with the analysis of medical conditions at a molecular level but also consultation on the diagnosis and empower them with personalised medical treatment.


Molecular Oncology
Fetal Maternal Health
Allergy & Molecular Allergology


With CAP (College of American Pathologists) certification for laboratory facilities, we will ensure that we can provide you with the highest standards of quality service trusted by clinicians and patients. CAP is the world’s largest association composed exclusively of pathologists certified by the American Board of Pathology. It serves more than 17,000 physician members. CAP is internationally recognised as the ‘gold standard’ for clinical laboratories.


Laboratory in Singapore
CAP# 9037462
First accreditation date: September 24, 2015


Molecular Pathology


Laboratory in Hong Kong
CAP# 9255784
First accreditation date: October 13, 2015
Molecular, Cytogenetics and Allergy


Angsana Molecular & Diagnostics aims to be a life care company committed to better healthcare for humanity’s tomorrow.


We are a diverse team of dedicated experts collectively committed to helping individuals and communities in Asia manage their healthcare conditions, so they not only live better, but also smarter. Driven to continuously improve, we provide cutting edge molecular diagnostic services, actionable personalised medical insights and practical public education to empower doctors and patients in making better informed decisions.



As taking care of your life should be a long term journey, we believe for real transformation to take place, a long term view is essential for ensuring sustainable change and success.



We champion the potential life-changing impact of Molecular Diagnostics and are determined to contribute to fulfilling this noble purpose for humanity.



Appreciating the privilege in enhancing people’s lives, we honour our commitments with the highest integrity.



Keeping an open and curious mind, we believe in continuous improvement and better ways, not just to live well, but to live smarter.



For progress in life care to truly happen, we feel that it is our responsibility to transfer knowledge to empower others to make informed decisions.



The symbol is derived from the shape of the Angsana fruit or seed, with links to the medicinal qualities of the tree and the idea of new life. The organic form of the seed also echoes the fluid shape of a human cell under a microscope. The seed is expressed in a series of radiating contours representing the growth of Angsana as it ripples outwards across Asia, reflecting the unique ability of the Angsana to rapidly disperse its seeds.




Angsana Molecular & Diagnostics is founded by a diversified team of leading Asian Clinical Scientists, prominent Healthcare Leaders and Business Directors.



Founding CEO


Dr Chris Tan brings more than fifteen years of experience in healthcare, life science and molecular diagnostic sales, marketing, business development and commercial operations across emerging and Fortune 500 companies.Previously, he worked in Thermo Fisher Scientific, the world leader in Life Science and Molecular Diagnostics where he served as the VP, Commercial Operations for APAC, Bioscience Division, representing the Life Science, Molecular Diagnostic, Chemical and Bio processing Business with a revenue responsibility of US$200M (Direct and Channel).


Prior to that, he was with Agilent as Business Development Director, Molecular Diagnostics, Asia Pacific. In this role, he successfully formulated and executed the Agilent Asia Pacific Diagnostics’ market development plan including different technology platforms like Microarray, QPCR and LCMS for the launch of the next generation molecular diagnostics business. He also led the Agilent, Life Science Research business for Asia Pacific and Japan where his team revamped and rapidly expanded Agilent’s life science products to the Asia Pacific region focusing on clinical solutions in molecular cytogenetics especially on microarray and next generation sequencing.


Prior to Agilent, Dr Chris Tan was the senior Sales and Marketing Director for Affymetrix where he established Affymetrix to be No 1 market leader in the Asia Pacific for Microarray. He started his career at Parkway Healthcare, the largest premier private hospital group and clinical lab in the Asia Pacific, where he held various positions in Business Development for the clinical lab and hospital operations. A graduate of National University of Singapore (Chemistry), he was awarded MSc and PhD in Biochemistry at University of Newcastle Upon Tyne, UK.



MB,BS, MD (Singapore), PhD (London), FRCPath (UK), FRCPA (Australia), FCAP (USA), FCFPS (Hon), FAMS, PPA, Officier dans l’Ordre  des Palmes Academiques.
Medical Director


Professor Edward Peng Chong Tock is currently an Emeritus Professor with the Department of Pathology at the National University of Singapore (NUS) and an Emeritus Consultant with the Department of Pathology at the National University Hospital (NUH), Singapore. He graduated in Medicine (MB,BS) from the then University of Malaya in Singapore in 1959. He commenced his career in Pathology at the then University of Singapore in 1961, rising through the ranks of Assistant Lecturer, Lecturer, Senior Lecturer, Associate Professor and Professor. He was a Senior Consultant in Pathology at the Singapore General Hospital till 1985, when he moved to the National University Hospital as Senior Consultant and Head of the Department of Pathology, concurrently being the Professor and Head of the Department of Pathology at NUS. He served as the Dean of the Faculty of Medicine of NUS, and as Chairman of the Medical Board of NUH, for several years. He has also served in numerous boards and committees in NUS, Ministry of Health, and other public bodies. He has served as External Examiner in Pathology in many overseas Universities and professional bodies, at undergraduate and postgraduate levels.


Professor Tock underwent training in Pathology at the Singapore General Hospital, obtaining MD in Pathology by research. He then trained at the Hammersmith Hospital, Royal Postgraduate Medical School of London, where he obtained his PhD in Pathology. He became professionally qualified as a specialist in Pathology (in the field of Anatomical Pathology), obtaining the Fellowships of the Royal College of Pathologists of Australasia, the Royal College of Pathologists of the United Kingdom, and the College of American Pathologists. He has published extensively, with over one hundred scientific papers in local, regional and international journals, and presented numerous conference papers, including many overseas in Europe, Australia, and North America.


Professor Tock was awarded the Public Administration Medal from the Singapore Government, the French knighthood of Officier dans l’Ordre des Palmes Academiques, the Lee Foundation-National Healthcare Group Life Time Achievement Award, Emeritus Consultant status in Pathology in NUH, Emeritus Professorship in Pathology in NUS, and several other awards.



The team is supported by a world-class Scientific Advisory Board comprising thought leaders and practitioners from Asia and the United States who provide scientific direction and strategic guidance to help us stay ahead in the field.


Our partnerships with leading pharmaceutical and biotechnology companies as well as academic institutions enable us to continually advance our research and development to support our services to clinicians and patients.

Thermo Fisher Scientific Inc.

Our partnership with Thermo Fisher Scientific Inc aims to develop expertise and knowledge in the area of molecular diagnostics and its applications for the Asian population; as well as creating an awareness of Molecular Allergology assays and expanding their adoption in South East Asia and North Asia.


Agilent Technologies

Our partnership with Agilent Technologies aims to develop expertise and knowledge in the area of molecular diagnostic applications for the genetic diagnostic markets including cancer, postnatal, prenatal and pre-implantation genetic screening and diagnosis.


PerkinElmer Pte Ltd

Our partnership with PerkinElmer aims to harness our complementary resources to promote products and services in the area of maternal screening, prenatal testing and cancer diagnostics for the Asian population.



Angsana Molecular & Diagnostics Laboratory Pte Ltd
No. 1 Science Park Road
#04-10, The Capricorn
Science Park II
Singapore 117528

T: (65) 6873 9959
F: (65) 6873 9860
E: [email protected]



Angsana Molecular & Diagnostics Laboratory (HK) Ltd
Unit 311-312 & 315
16W Science Park West Avenue
Hong Kong Science Park
Shatin, NT, Hong Kong

T: (852) 2793 0782
F: (852) 2793 0630
E: [email protected]

The healthcare landscape is changing. In this decade, Molecular Diagnostics will leave a legacy to humankind.